There is evidence to suggest that CDK4/6i can increase tumor cell sensitivity to proton therapy through impaired RAD51 foci formation (19), but at present, our understanding of the relationship between simultaneous radiation treatment and CDK4/6 inhibitor therapy in the treatment of TNBC is insufficient. Here, CDK4 is linked to neoplasm.